Name: 글로벌 시장 동향
SKU: PH7768
Availability: InStock

보고서 요약(국문)

개요
전 세계 비정형 용혈성 요세포증후군(aHUS) 치료 시장은 2022년 XX백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 XX%의 성장률을 보이며 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
비정형 용혈성 요세포증후군(aHUS)은 작은 혈전과 장기 손상을 유발하는 잠재적으로 생명을 위협하는 질환입니다. 이는 종종 면역 체계에 영향을 미치는 유전적 돌연변이에 의해 발생합니다. aHUS는 혈관에 미세한 혈전이 형성되어 중요한 장기로의 혈류를 차단하는 매우 드문 유전 질환입니다. aHUS는 신부전, 심장 질환 및 기타 심각한 건강 문제를 유발할 수 있습니다.
비정형 용혈성 요세포증후군은 전혈구 검사(CBC) 및 신장 기능 검사, 유전자 검사, 대변 검사, 신장 생검 등 여러 검사를 통해 진단할 수 있습니다.

시장 동향: 성장 동력 및 제약 요인
치료법의 증가
새로운 치료 대안의 도입과 환자들의 질병 인식 제고에 힘입어 시장이 확대될 것으로 예상됩니다. 최근 개발된 치료제들은 aHUS의 근본 원인인 보체 조절 장애에 초점을 맞추고 있습니다.
aHUS 환자들에게 이러한 치료법은 새로운 치료의 길을 열어줍니다. 여러 국가에서 과학적 연구를 통해 aHUS와 같은 희귀 질환 연구를 장려하고 있습니다. aHUS에 대한 이해가 깊어짐에 따라 환자, 보호자, 의료 전문가들의 인식도 높아지고 있습니다. 이러한 지식 증진을 통해 조기 진단 및 치료가 가능해지면서 환자들의 치료 결과도 개선되고 있습니다.
제약 요인
높은 치료 비용
aHUS 치료 비용은 매우 높을 수 있으며, 이는 일부 환자들의 치료 접근성을 제한할 수 있습니다. 높은 비용은 질병의 복잡성, 전문적인 치료의 필요성, 그리고 상대적으로 적은 환자 수 때문입니다. 따라서 이러한 요인들은 시장 성장을 저해할 것으로 예상됩니다.

시장 세분화 분석
전 세계 비정형 용혈성 요세포증후군(aHUS) 치료 시장은 치료 유형, 최종 사용자 및 지역별로 세분화됩니다.
정맥 스텐트 부문이 시장 점유율의 56.3%를 차지했습니다.
비정형 용혈성 요세포증후군(aHUS)은 보체 시스템의 조절 장애로 인해 보체가 과활성화되는 질환입니다. 약물 치료 부문은 다른 유형의 치료법보다 시장에서 지배적인 위치를 차지하고 있는데, 이는 약물의 안전성과 질병 치료 효과 때문입니다.
에쿨리주맙은 말단 보체 경로를 차단하는 새로 개발된 생물학적 제제로, aHUS 치료에 성공적으로 사용되고 있습니다. aHUS에 대해 유일하게 승인된 치료제인 에쿨리주맙(솔리리스)은 인간 C5 보체 단백질에 높은 친화도로 결합하여 염증성 C5a와 용해성 C5b의 생성을 차단하는 인간화 단클론 항체입니다.

라불리주맙은 미국과 유럽연합을 포함한 여러 국가에서 비정형 용혈성 요독증후군(aHUS) 치료제로 승인되었습니다. 라불리주맙은 에쿨리주맙을 재설계하여 최종 소실 반감기를 연장함으로써, 에쿨리주맙의 2~3주 간격 투여보다 편리한 4~8주 간격의 유지 용량 투여가 가능해졌습니다. 이러한 요인들이 시장을 주도할 것으로 예상됩니다.
지역 분석
북미는 전 세계 비정형 용혈성 요독증후군 치료 시장에서 상당한 비중을 차지할 것으로 예상됩니다.
북미는 시장 점유율에서 주도적인 위치를 차지할 것으로 예상됩니다. 다른 지역에 비해 북미는 aHUS 발병률이 상대적으로 높아 aHUS 치료에 대한 수요가 높습니다. 북미는 의료 산업 분야에서 오랜 혁신과 기술 개발 역사를 바탕으로 aHUS에 대한 새로운 치료법과 치료제가 개발되어 왔습니다. 이 지역은 최첨단 의료 시설과 우수한 의료진을 갖춘 활발한 의료 부문을 자랑하며, 이는 aHUS 환자 치료 수준 향상에 기여하고 있습니다.
북미 각국 정부는 aHUS를 포함한 희귀 질환 연구를 장려하기 위한 조치를 취하고 있으며, 이러한 지원은 새로운 치료법 개발을 촉진하고 기존 치료법에 대한 접근성을 개선하고 있습니다. 북미 지역의 환자, 보호자, 의료 전문가들 사이에서 aHUS에 대한 인식이 높아지고 있으며, 이는 조기 진단 및 치료로 이어지고 있습니다.
코로나19 영향 분석
코로나19는 시장 성장에 상당한 영향을 미쳤습니다. 승인 및 출시 지연으로 인해 환자들이 필요한 의약품을 구하기 어려워졌습니다. 제약 회사들은 코로나19 치료제 생산에 집중했으며, 봉쇄 조치 시행으로 공급망이 차질을 빚었습니다.

시장 세분화
치료 유형별
• 약물 유형
o 에쿨리주맙
o 라불리주맙
• 시술
o 혈장 치료
o 투석
o 신장 이식
최종 사용자별
• 병원
• 전문 클리닉
• 외래 수술 센터
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
주요 기업으로는 Alexion Pharmaceuticals, Inc., Novartis AG, AstraZeneca Plc, GNHIndia, Omeros Corporation, Chugai Pharmaceutical Co., Ltd., Bio-Rad Laboratories, Inc. 등이 있으며, 이들 기업은 상당한 시장 점유율을 차지하고 있습니다. 그 외
보고서 구매 이유

• 치료 유형, 최종 사용자 및 지역별 전 세계 비정형 용혈성 요세포증후군 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 비정형 용혈성 요세포증후군 치료 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 Excel 파일을 제공합니다.

전 세계 비정형 용혈성 요세포증후군 치료 시장 보고서는 약 47개의 표, 48개의 그림, 176페이지로 구성됩니다.
대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Atypical Hemolytic Uremic Syndrome Treatment Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing at a CAGR of XX% during the forecast period 2023-2030.
Atypical hemolytic uremic syndrome (aHUS) is a potentially life-threatening condition that causes small blood clots and organ damage. It’s often caused by a genetic mutation that affects the immune system. It is a very rare genetic disease that causes tiny blood clots to form in your blood vessels, blocking blood flow to important organs. aHUS can cause kidney failure, heart disease, and other serious health problems.
The atypical hemolytic uremic syndrome can be diagnosed with several tests that include complete blood count (CBC) and kidney function tests, genetic testing, stool tests, kidney biopsy and others.
Market Dynamics: Drivers & Restraints
Increase in the availability of treatments
Market expansion is anticipated to be driven by the growing number of treatment alternatives being introduced and the rising level of patient awareness. The fundamental causes of aHUS, such as complement dysregulation, are the focus of recently developed therapeutics.
For those suffering from aHUS, these therapies provide novel avenues for treatment. Numerous nations are promoting research on uncommon diseases, such as aHUS, through scientific initiatives. Patients, caregivers, and medical professionals are becoming increasingly aware of aHUS as more is known about the condition. Patient outcomes are being improved by the early diagnosis and treatment of aHUS brought about by this greater knowledge.
Restraint
High cost of the treatment
The cost of aHUS treatment can be very high, which can limit access to care for some patients. The high cost is due to the complexity of the disease, the need for specialized treatment, and the relatively low patient population. Thus, the above factors are expected to hinder the market growth.
Segment Analysis
The global atypical hemolytic uremic syndrome treatment market is segmented based on treatment type, end-user, and region.
Venous Stents segment accounted for 56.3% of the market share
Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the complement system, leading to complement overactivation. Drugs segment holds a dominant position over other types of treatments. This is due to their safety and efficiency in the treatment of the disease.
Eculizumab is a newly developed biologic that blocks the terminal complement pathway and has been successfully used in the treatment of aHUS. Eculizumab (Soliris), the only approved treatment for aHUS,15, 16 is a humanized monoclonal antibody that binds with high affinity to the human C5 complement protein and blocks the formation of proinflammatory C5a and lytic C5b.
Ravulizumab is approved for the treatment of atypical hemolytic uraemic syndrome (aHUS) in several countries, including the United States and the European Union. Ravulizumab was re-engineered from eculizumab to have a longer terminal elimination half-life, resulting in a more convenient maintenance dose regimen of once every 4-8 weeks versus once every 2-3 weeks for eculizumab. Thus, the above factors are expected to hold the segment in the dominant position.
Geographical Analysis
North America is expected to hold a significant position in the global atypical hemolytic uremic syndrome treatment market share
North America is expected to hold a dominant position in the market share. In comparison to other locations, North America has a comparatively high frequency of aHUS, which raises the need for aHUS treatment. New treatments and cures for aHUS have been developed as a result of North America's long history of innovation and technology developments in the healthcare industry. The area also boasts a thriving healthcare sector with cutting-edge medical facilities and highly qualified medical personnel, all of which improve the standard of care for patients with aHUS.
Governments in North America are taking steps to promote research into rare diseases, including aHUS, and this support is driving the development of new therapies and improving access to existing treatments. There is growing awareness of aHUS among patients, caregivers, and healthcare professionals in North America, leading to earlier diagnosis and treatment of the disease.
COVID-19 Impact Analysis
COVID-19 has had a significant impact on the growth of the market. The delayed approvals and launches have caused the lack of availability of drugs to the patients. The companies have shifted their focus towards the manufacturing of COVID-19 medicine. The supply chains have been interrupted due to the implementation of the lockdown.
Market Segmentation
By Treatment Type
• Drug Type
o Eculizumab
o Ravulizumab
• Procedure
o Plasma Therapy
o Dialysis
o Kidney Transplant
By End-User
• Hospital
• Specialty Clinics
• Ambulatory Surgical Centers
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The leading companies with a significant market share include Alexion Pharmaceuticals, Inc., Novartis AG, AstraZeneca Plc, GNHIndia, Omeros Corporation, Chugai Pharmaceutical Co., Ltd., and Bio-Rad Laboratories, Inc. and among others. among others
Why Purchase the Report?
• To visualize the global atypical hemolytic uremic syndrome treatment market segmentation based on treatment type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of atypical hemolytic uremic syndrome treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global atypical hemolytic uremic syndrome treatment market report would provide approximately 47 tables, 48 figures, and 176 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment Type
3.2. Snippet by End-User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increase in the availability of treatments
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. High cost of the treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. Treatment Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
7.1.2. Market Attractiveness Index, By Treatment Type
7.2. Drug Type
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Eculizumab
7.2.4. Ravulizumab
7.3. Procedure
7.3.1. Plasma Therapy
7.3.2. Dialysis
7.3.3. Kidney transplant
8. By End-User
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.1.2. Market Attractiveness Index, By End-User
8.2. Hospital
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Ambulatory Surgical Centers
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.5.1. U.S.
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.5.1. Germany
9.3.5.2. UK
9.3.5.3. France
9.3.5.4. Italy
9.3.5.5. Spain
9.3.5.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.5.1. Brazil
9.4.5.2. Argentina
9.4.5.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.5.1. China
9.5.5.2. India
9.5.5.3. Japan
9.5.5.4. Australia
9.5.5.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Alexion Pharmaceuticals, Inc. *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Novartis AG
11.3. AstraZeneca Plc
11.4. GNHIndia
11.5. Omeros Corporation
11.6. Chugai Pharmaceutical Co., Ltd.
11.7. Bio-Rad Laboratories, Inc.
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us

언급된 주요 기업들

Alexion Pharmaceuticals, Inc., 4.	Key Developments, Novartis AG, AstraZeneca Plc, GNHIndia, Omeros Corporation, Chugai Pharmaceutical Co., Ltd., Bio-Rad Laboratories, Inc.

표 목록 (Tables)

List of Tables

Table 1 Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Treatment Type, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 6 Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 8 Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Region, 2022-2031 (US$ Million)

Table 10 North America Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 11 North America Atypical Hemolytic Uremic Syndrome Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 12 North America Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 13 South America Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 14 South America Atypical Hemolytic Uremic Syndrome Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 15 South America Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 16 Europe Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 17 Europe Atypical Hemolytic Uremic Syndrome Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 18 Europe Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 19 Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 20 Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 21 Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Country, 2022-2031 (US$ Million)

Table 22 Middle East & Africa Atypical Hemolytic Uremic Syndrome Treatment Market Value, By Treatment Type, 2022-2031 (US$ Million)

Table 23 Middle East & Africa Atypical Hemolytic Uremic Syndrome Treatment Market Value, By End-User, 2022-2031 (US$ Million)

Table 24 Alexion Pharmaceuticals, Inc.: Overview

Table 25 Alexion Pharmaceuticals, Inc.: Product Portfolio

Table 26 Alexion Pharmaceuticals, Inc.: Key Developments

Table 27 Novartis AG: Overview

Table 28 Novartis AG: Product Portfolio

Table 29 Novartis AG: Key Developments

Table 30 AstraZeneca Plc: Overview

Table 31 AstraZeneca Plc: Product Portfolio

Table 32 AstraZeneca Plc: Key Developments

Table 33 GNHIndia: Overview

Table 34 GNHIndia: Product Portfolio

Table 35 GNHIndia: Key Developments

Table 36 Omeros Corporation: Overview

Table 37 Omeros Corporation: Product Portfolio

Table 38 Omeros Corporation: Key Developments

Table 39 Chugai Pharmaceutical Co., Ltd.: Overview

Table 40 Chugai Pharmaceutical Co., Ltd.: Product Portfolio

Table 41 Chugai Pharmaceutical Co., Ltd.: Key Developments

Table 42 Bio-Rad Laboratories, Inc.: Overview

Table 43 Bio-Rad Laboratories, Inc.: Product Portfolio

Table 44 Bio-Rad Laboratories, Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 2 Global Atypical Hemolytic Uremic Syndrome Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 3 Global Atypical Hemolytic Uremic Syndrome Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 4 Global Atypical Hemolytic Uremic Syndrome Treatment Market Share, By Region, 2023 & 2031 (%)

Figure 5 Global Atypical Hemolytic Uremic Syndrome Treatment Market Y-o-Y Growth, By Treatment Type, 2023-2031 (%)

Figure 6 Drug Type Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 7 Procedure Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 8 Global Atypical Hemolytic Uremic Syndrome Treatment Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 9 Hospital End-User in Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 10 Specialty Clinics End-User in Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 11 Ambulatory Surgical Centers End-User in Global Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 12 Global Atypical Hemolytic Uremic Syndrome Treatment Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 13 North America Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 14 Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 15 Europe Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 16 South America Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 17 Middle East and Africa Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 18 North America Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 19 North America Atypical Hemolytic Uremic Syndrome Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 20 North America Atypical Hemolytic Uremic Syndrome Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 21 North America Atypical Hemolytic Uremic Syndrome Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 22 South America Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 23 South America Atypical Hemolytic Uremic Syndrome Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 24 South America Atypical Hemolytic Uremic Syndrome Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 25 South America Atypical Hemolytic Uremic Syndrome Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 26 Europe Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 27 Europe Atypical Hemolytic Uremic Syndrome Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 28 Europe Atypical Hemolytic Uremic Syndrome Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 29 Europe Atypical Hemolytic Uremic Syndrome Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 30 Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 31 Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 32 Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 33 Asia-Pacific Atypical Hemolytic Uremic Syndrome Treatment Market Share, By Country, 2023 & 2031 (%)

Figure 34 Middle East & Africa Atypical Hemolytic Uremic Syndrome Treatment Market Value, 2022-2031 (US$ Million)

Figure 35 Middle East & Africa Atypical Hemolytic Uremic Syndrome Treatment Market Share, By Treatment Type, 2023 & 2031 (%)

Figure 36 Middle East & Africa Atypical Hemolytic Uremic Syndrome Treatment Market Share, By End-User, 2023 & 2031 (%)

Figure 37 Alexion Pharmaceuticals, Inc.: Financials

Figure 38 Novartis AG: Financials

Figure 39 AstraZeneca Plc: Financials

Figure 40 GNHIndia: Financials

Figure 41 Omeros Corporation: Financials

Figure 42 Chugai Pharmaceutical Co., Ltd.: Financials

Figure 43 Bio-Rad Laboratories, Inc.: Financials

글로벌 비정형 용혈성 요독증후군 치료 시장 – 2023-2030

Global Atypical Hemolytic Uremic Syndrome Treatment Market - 2023-2030